These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2425059)

  • 21. Cardiovascular adaptation to obesity and hypertension.
    Lavie CJ; Messerli FH
    Chest; 1986 Aug; 90(2):275-9. PubMed ID: 2942341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hemodynamic and hormonologic basis of the treatment of arterial hypertension].
    Guédon J; Lucsko M; Chaignon M
    Arch Mal Coeur Vaiss; 1974 Oct; 67(10):1145-55. PubMed ID: 4156640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obesity in hypertension: how innocent a bystander?
    Messerli FH
    Am J Med; 1984 Dec; 77(6):1077-82. PubMed ID: 6239545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects.
    MacCarthy EP; Bloomfield SS
    Pharmacotherapy; 1983; 3(4):193-219. PubMed ID: 6310529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term hemodynamic effects of antihypertensive treatment.
    Lund-Johansen P; Omvik P; Nordrehaug JE
    Clin Investig; 1992; 70 Suppl 1():S58-64. PubMed ID: 1350486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of hypertension in the elderly with labetalol.
    Sirgo MA; Boyd BK; Applegate WB
    Pharmacotherapy; 1989; 9(5):295-302. PubMed ID: 2682551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin.
    Omvik P; Lund-Johansen P
    Cardiovasc Drugs Ther; 1993 Apr; 7(2):193-206. PubMed ID: 8395198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Borderline hypertension: relationship between age, hemodynamics and circulating catecholamines.
    Messerli FH; Frohlich ED; Suarez DH; Reisin E; Dreslinski GR; Dunn FG; Cole FE
    Circulation; 1981 Oct; 64(4):760-4. PubMed ID: 7273377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regression of cardiac hypertrophy with drug treatment in spontaneously hypertensive rats.
    Ruskoaho H
    Med Biol; 1984; 62(5):263-76. PubMed ID: 6152298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity.
    Messerli FH; Christie B; DeCarvalho JG; Aristimuno GG; Suarez DH; Dreslinski GR; Frohlich ED
    Arch Intern Med; 1981 Jan; 141(1):81-5. PubMed ID: 7004372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Hemodynamic guidelines in the treatment of acute myocardial infarction by means of vasodilators].
    Zilcher H
    Acta Med Austriaca Suppl; 1979; 15():1-34. PubMed ID: 161946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antihypertensive therapy: newer concepts and agents.
    Frohlich ED
    Cardiology; 1985; 72(5-6):349-65. PubMed ID: 2866842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemodynamic role of extracellular fluid in hypertension.
    Tarazi RC
    Circ Res; 1976 Jun; 38(6 Suppl 2):73-83. PubMed ID: 773571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.
    Frishman WH
    Cardiovasc Drugs Ther; 1988 Sep; 2(3):343-53. PubMed ID: 2908732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Haemodynamic effects of combined alpha- and beta-adrenoreceptor blockade after intravenous labetalol in hypertensive patients at rest and during exercise.
    Koch G
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):725-8. PubMed ID: 10950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of labetalol with other anti-hypertensive drugs.
    Prichard BN; Richards DA
    Br J Clin Pharmacol; 1982 Jun; 13(1 Suppl):41S-47S. PubMed ID: 6124265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects.
    Mehta J; Cohn JN
    Circulation; 1977 Feb; 55(2):370-5. PubMed ID: 12880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute hemodynamic and neurohumoral profile of dilevalol in hypertensive patients with ischemic heart disease.
    Remme WJ; von Schelven D; Bartels GL; Kruijssen HA; de Leeuw PW
    J Cardiovasc Pharmacol; 1993 Aug; 22(2):327-35. PubMed ID: 7692177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study.
    Higashi Y; Sasaki S; Nakagawa K; Ueda T; Yoshimizu A; Kurisu S; Matsuura H; Kajiyama G; Oshima T
    J Am Coll Cardiol; 2000 Feb; 35(2):284-91. PubMed ID: 10676671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disparate cardiovascular effects of obesity and arterial hypertension.
    Messerli FH; Sundgaard-Riise K; Reisin E; Dreslinski G; Dunn FG; Frohlich E
    Am J Med; 1983 May; 74(5):808-12. PubMed ID: 6340494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.